Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar

Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar

Submitted by admin on July 22, 2015 - 9:36pm
Source: 
Fierce Pharma Marketing
News Tags: 
biosimilars
AbbVie
Roche
Amgen
Rituxan
Herceptin
Avastin
Neupogen
Neulasta
Epogen
Humira
Perjeta
Gazyva
Headline: 
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar

Do Not Allow Advertisers to Use My Personal information